Company intelligence / Profile preview

Ciatrix

St. Louis Park, Minnesota, USAciatrix.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Ciatrix has announced the registration of the REGLYDE clinical trial, which investigates a novel computerized yoga movement technology as an intervention for Alzheimer’s disease. The approach represents a non-drug digital therapeutic strategy targeting cognitive decline in affected patients. No published results are available yet.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Ciatrix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ciatrix.

Explore the full profile